PROLIFERATIVE AND APOPTOTIC STATUS ON LYMPH NODE SECTIONS, INCLUDING THE PROLIFERATION CENTERS (PC), OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS

被引：0
|
作者：
Sachanas, S. [1 ]
Levidou, G. [2 ]
Angelopoulou, M. [3 ]
Moschogiannis, M. [2 ]
Yiakoumis, X. [2 ]
Vassilakopoulos, T. [3 ]
Kyrtsonis, M. C. [3 ]
Kontopidou, F. [3 ]
Kalpadakis, C. [4 ]
Tsirkinidis, P. [5 ]
Dimitriadou, E. [1 ]
Dimitrakopoulou, A. [6 ]
Kokoris, S. [7 ]
Panayiotidis, P. [3 ]
Papadaki, H. [4 ]
Patsouris, E. [3 ]
Korkolopoulou, P. [3 ]
Pangalis, G. [1 ]
机构：
[1] Athens Med Ctr, Phychikon Branch, Athens, Greece
[2] Athens Med Ctr, Athens, Greece
[3] Univ Athens, Athens, Greece
[4] Univ Crete, Haematol Dept, Iraklion, Greece
[5] 401 Mil Hosp, Athens, Greece
[6] Laikon Gen Hosp, Athens, Greece
[7] Attikon Gen Hosp, Athens, Greece
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0731
引用
收藏
页码：297 / 297
页数：1
相关论文
共 50 条
  • [31] THERAPY PROGRAM FOR PATIENTS WITH ADVANCED STAGES OF CHRONIC LYMPHOCYTIC-LEUKEMIA - CHLORAMBUCIL, SPLENECTOMY, AND TOTAL LYMPH-NODE IRRADIATION
    PEGOURIEBANDELIER, B
    SOTTO, JJ
    HOLLARD, D
    BOLLA, M
    SARRAZIN, R
    CANCER, 1995, 75 (12) : 2853 - 2861
  • [32] MYC Plays an Important Role in the Proliferation Centers of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), but Does Not Explain the Presence of Cyclin D1 Expression in a Subset of Cases
    Jain, S.
    Swerdlow, S. H.
    Bullock, G. C.
    Gibson, S. E.
    MODERN PATHOLOGY, 2014, 27 : 353A - 353A
  • [33] MYC Plays an Important Role in the Proliferation Centers of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), but Does Not Explain the Presence of Cyclin D1 Expression in a Subset of Cases
    Jain, S.
    Swerdlow, S. H.
    Bullock, G. C.
    Gibson, S. E.
    LABORATORY INVESTIGATION, 2014, 94 : 353A - 353A
  • [34] CLINICAL AND HEALTH-STATUS ASSESSMENTS IN ANEMIC CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) PATIENTS TREATED WITH EPOETIN-ALFA (EPO)
    ROSE, E
    RAI, K
    REVICKI, D
    BROWN, R
    REBLANDO, J
    BLOOD, 1994, 84 (10) : A526 - A526
  • [35] NanoString nCounter-based mRNA profiling of genes in chronic lymphocytic leukemia (CLL) cells derived from the blood, bone marrow and lymph node compartments.
    Crassini, Kyle
    Shen, Yandong
    Stevenson, William
    Mulligan, Stephen P.
    Best, Giles
    LEUKEMIA & LYMPHOMA, 2020, 61 : 67 - 69
  • [36] Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymph ocytic leukemia) with aggressive clinical behavior (Retraction of vol 95, pg 1526, 2010)
    Gine, Eva
    Martinez, Antonio
    Villamor, Neus
    Lopez-Guillermo, Armando
    Camos, Mireia
    Martinez, Daniel
    Esteve, Jordi
    Calvo, Xavier
    Muntanola, Ana
    Abrisqueta, Pau
    Rozman, Maria
    Rozman, Ciril
    Bosch, Francesc
    Campo, Elias
    Montserrat, Emili
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (09): : 1620 - 1620
  • [37] Incidence of arrhythmia in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib: a real-world retrospective analysis from two Italian centers.
    Murru, Roberta
    Innocenti, Idanna
    Galitzia, Andrea
    Tomasso, Annamaria
    Oggianu, Valeria
    Laurenti, Luca
    La Nasa, Giorgio
    LEUKEMIA & LYMPHOMA, 2023, 64 : S162 - S163
  • [38] Variation in health-related quality of life (HRQOL) by ECOG performance status (PS) and fatigue among patients with chronic lymphocytic leukemia (CLL).
    Flowers, Christopher
    Pashos, Chris L.
    Weiss, Mark Adam
    Lamanna, Nicole
    Farber, Charles Michael
    Kipps, Thomas J.
    Lerner, Susan
    Kay, Neil E.
    Sharman, Jeff Porter
    Grinblatt, David L.
    Flinn, Ian W.
    Kozloff, Mark
    Swern, Arlene S.
    Khan, Zeba M.
    Street, Thomas
    Sullivan, Kristen
    Keating, Michael J.
    Yu, Ren
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY)
    Scarfo, L.
    Quaresmini, G.
    Mauro, F. R.
    Orlandi, E.
    Reda, G.
    Laurenti, L.
    Coscia, M.
    Ambrosetti, A.
    Murru, R.
    Trentin, L.
    Guelill, A.
    Visco, C.
    Morabito, F.
    Frustaci, A.
    Ciolli, S.
    Rossini, F.
    Cuneo, A.
    Gozzetti, A.
    Scortechini, I.
    Pane, F.
    Zinzani, P. L.
    Ferrara, F.
    Mannina, D.
    Marasca, R.
    Pierri, I.
    Specchia, G.
    Chiarenza, A.
    Zallio, F.
    Molica, S.
    De Paoli, L.
    Torreggiani, A.
    Brugiatelli, M.
    Semenzato, G.
    Innocenti, I.
    Picardi, P.
    Pizzolo, G.
    Foa, R.
    Rambaldi, A.
    Ghia, P.
    HAEMATOLOGICA, 2015, 100 : 227 - 227
  • [40] The Src-AbI kinase inhibitor dasatinib (BMS-354825). shows anti-proliferative and anti-apoptotic effects in chronic lymphocytic leukemia (CLL) cells in vitro.
    Veldurthy, Aditya
    Patz, Michaela
    Pallasch, Christian P.
    Fendtner, Clemens M.
    Hallek, Michael
    Krause, Gunter F.
    BLOOD, 2007, 110 (11) : 912A - 912A
12345